Drug Trial Radar · NCT06440694
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 7, 2025
Primary completion
Dec 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Ottawa Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial seeks to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (PTS) in patients with proximal lower extremity deep vein thrombosis (DVT).
Conditions
- Venous Thromboembolism
Interventions
Colchicine 0.5 mg poDrug
Colchicine 0.5 mg po once daily for 180 days.
Placebo 0.5 mg poDrug
Placebo 0.5 mg po once daily for 180 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pilot Trial Primary Outcome: Recruitment RateTime frame: 12 months
- Full-Scale Trial Primary Outcome: Post Thrombotic SyndromeTime frame: 180 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The Ottawa Hospital General Campus
Ottawa, Ontario, Canada · Recruiting
Windsor Regional Hospital
Windsor, Ontario, Canada · Recruiting
Centre de recherche du Centre hospitalier de l'Université de Montréal
Montreal, Quebec, Canada · Recruiting
The Sir Mortimer B. Davis Jewish General Hospital
Montreal, Quebec, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.